Tezepelumab Granted Priority Review By U.S. FDA

THOUSAND OAKS, Calif., July 7, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news